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Abstract
Myosin-1C (MYO1C) is a tumor suppressor candidate located in a region of recurrent
losses distal to TP53. Myo1c can tightly and specifically bind to PIP2, the substrate of Phos-
phoinositide 3-kinase (PI3K), and to Rictor, suggesting a role for MYO1C in the PI3K path-
way. This study was designed to examine MYO1C expression status in a panel of well-
stratified endometrial carcinomas as well as to assess the biological significance of
MYO1C as a tumor suppressor in vitro. We found a significant correlation between the
tumor stage and lowered expression of MYO1C in endometrial carcinoma samples. In cell
transfection experiments, we found a negative correlation between MYO1C expression
and cell proliferation, and MYO1C silencing resulted in diminished cell migration and adhe-
sion. Cells expressing excess of MYO1C had low basal level of phosphorylated protein
kinase B (PKB, a.k.a. AKT) and cells with knocked down MYO1C expression showed a
quicker phosphorylated AKT (pAKT) response in reaction to serum stimulation. Taken
together the present study gives further evidence for tumor suppressor activity of MYO1C
and suggests MYO1C mediates its tumor suppressor function through inhibition of PI3K
pathway and its involvement in loss of contact inhibition.
Introduction
Aminimal region of recurrent deletion/allelic loss distal to the Tp53 gene was identified in an
experimental rat model for endometrial carcinoma [1]. Deletions at the homologous position
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on human chromosome 17 (17p13.3) unassociated with TP53mutation have been reported in
several types of human tumors [2–5], suggesting a tumor suppressor activity in this chromo-
somal region. In deletionmapping, combined with gene expression, sequencing and epigenetic
silencing, the candidate region was delimited andMyo1c was identified as one of the most likely
candidates for the proposed tumor suppressor activity [6].
MYO1C encodes a class I unconventional myosin [7, 8], which is implicated, among other
possible functions, in angiogenic signaling [9], glucose uptake [10–12] and the progression of
the cell cycle [13]. TheMYO1C gene is located on human chromosome 17 and encodes three
isoforms of myosin-1c protein, two of which are found in the nucleus and cytoplasm, while the
third is found exclusively in the nucleus [14–16]. Myo1c can bind tightly and specifically to
PIP2 (phosphatidylinositol 4,5-bisphosphate) and InsP3 (inositol 1,4,5-trisphosphate) seem-
ingly through its putative pleckstrin homology domain [17, 18]. When PIP2 localizes to lipid
rafts in podocytes,myosin-1c becomes spatially associated with lipid rafts through this tight
binding [19]. PIP2 is an important secondmessenger involved in some crucial cellular func-
tions, including the regulation of the cytoskeleton and vesicle movements [20]. Myo1c is essen-
tial for the trafficking, translocation and fusion of exocyticGLUT4 (glucose transporter type
4)-containing vesicles with the plasma membrane upon insulin stimulation in muscle and adi-
pose tissue [10–12, 21]. Depletion of Myo1c or over-expression of dominant-negative forms of
the protein impaired this function in mouse fibroblasts [10, 22]. Insulin-stimulated phosphory-
lation of Myo1c is important for translocation of GLUT4-vesicles [23, 24] as well as for docking
or fusion of GLUT4-vesicles to the membrane through reinforcement of Myo1c binding with
the PI3K/AKT signaling pathway regulatory 14-3-3 protein that is associated with an increased
ATPase activity of Myo1c [23, 25]. There is no earlier report on potential tumor suppressor
activity ofMYO1C; however, another member of the myosin-I gene family, MYO18B, has been
recognized as a tumor suppressor gene candidate in lung, ovarian and colorectal cancer [26,
27].
Deregulation of the PI3K/AKT pathway is a recurrent feature in numerous human malig-
nancies with a key role in cancer development, progression and also in resistance to chemo-
therapy [28]. Over-activity of this pathway is commonly caused by loss of function of the
tumor suppressor gene PTEN [29, 30], oncogenic activation of PIK3CA [31, 32] and/or over-
stimulation by various growth factors, namely IGF-1, EGF or VEGF [33–35]. Although roles of
MYO1C in the insulin-mediated signaling for glucose receptor transport are well established,
details of its potential involvement in cancer development through the PI3K/AKT signaling
pathway remain to be investigated.
In the present work, we examined the level of MYO1C in a panel of well-stratified endome-
trial carcinomas to inspect the potential correlation of MYO1C protein levels with tumor stage
and prognosis. Our analysis showed a significant negative association betweenMYO1C protein
level and the endometrial carcinoma tumor stage. To investigate the potential mechanism/s
involved, we performed cell transfections for MYO1C protein over-expression and/or knock-
down followed by cell proliferation, cell migration, and cell spreading/adhesion assays to inves-
tigate the potential contribution ofMYO1C to these cancer phenotypes. As earlier works
suggest for potential involvement of MYO1C in the PI3K/AKT pathway, we additionally per-
formed protein level analyses for a number of key components of the PI3K/AKT signaling
pathway in cells with over-expression or lowered expression ofMYO1C in order to investigate
the nature and consequence of involvement of MYO1C in PI3K/AKT and RAS/ERK signaling.
Our analysis revealed a negative correlation between levels of MYO1C protein level and activa-
tion of PI3K/AKT signaling and cell proliferation. Our analysis additionally showed that low-
ered expression ofMYO1C resulted in impaired cell migration and cell adhesion.
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Material and Methods
Immunohistochemistry analysis of human endometrial carcinomas
All experiments on human tumor samples were approved by the local ethical committee (Sahl-
grenska Academy, University of Gothenburg). All participants provided their written informed
consent to participate in the study, all documents are archived at Sahlgrenska University Hos-
pital; This procedure was approved by the ethical committee. A total of 62 endometrial carci-
nomas– 19 highly differentiated stage I tumors, 24 moderately differentiated stage II tumors,
19 poorly differentiated stage III tumors, and 10 endometrial hyperplasias–were analyzed. The
tumor samples were randomly selected based on their pathology frommaterial in the tissue
bank of paraffin blocks. Immunohistochemistry was performed on paraffin sections from the
samples above, using conventional staining methods in an EnvisionR system. The slides were
pretreated with Tris-EDTA and stained with 1:50 rabbit anti-SKIP (S8948, Sigma Aldrich),
1:3000 rabbit anti-MYO1C (HPA001768, Sigma Aldrich). A section from lymphoid tissue was
used as a positive control for MYO1C. The slides were evaluated using conventional light
microscopy, regarding the following parameters: localization in cells of positive staining, level
of positivity (0-1-2-3-4) in the tumor cell population, and fraction of positive cells in the tumor
cell population. Corresponding slides stained with haematoxylin-eosin were available to deter-
mine areas of tumor in the sections.
Cell lines and cell culture
HEK-293 cells (human embryonic kidney cell line, American Type Culture Collection,ATCC,
USA) and HeLa cells (Henrietta Lacks’ cervical cancer cell line, Sigma-Aldrich/TheEuropean
Collectionof Cell Cultures, ECACC, UK) with limited de novo expression of MYO1C (Fig 1)
were used for gene expression transfection studies. The cell lines were cultured in DMEM
medium (21063–029, GIBCOby Life Technologies, USA), supplemented with 10% bovine
growth serum (BGS; SH30541.02, Hyclone by Thermo Scientific,USA), and 1% penicillin and
streptomycin (PEST; 100X; P11-010, PAA Laboratories, Pasching, Austria).
For the siRNA gene silencing experiment, the immortalizednormal breast epithelium
MCF10A cells (Michigan Cancer Foundation, ATCC, USA) with medium to high de novo
expression of MYO1C (Fig 1) were cultured, as described earlier [36], in DMEM/F12 medium
(31330–038, GIBCOby Life Technologies), supplemented with 5% horse serum (16050–122,
GIBCOby Life Technologies), 20 ng/ml epidermal growth factor (EGF; AF100-15, Peprotech,
USA), 0.5 mg/ml hydrocortisone (H-0888, Sigma-Aldrich), 100 ng/ml cholera toxin (C-8052,
Fig 1. Expression of MYO1C in human embryonic kidney HEK-293, cervical cancer HeLa, and normal
breast epithelium MCF10A cell lines. Immunoblot of MYO1C protein was performed in embryonic non-
cancerous HEK-293, adult non-cancerous MCF10A and adult cancerous (HeLa) cell lines. HeLa and HEK-
293 cells transfected with MYO1C expression construct were included as positive control and also to
examine the specificity of the MYO1C antibody. De novo expression of MYO1C was found to be low in the
embryonic HEK-293 and the cancerous HeLa cells, and high in the normal breast epithelial MCF10A cells.
Three independent experiments were performed and the figure shows a representative of these repeats.
doi:10.1371/journal.pone.0164063.g001
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Sigma-Aldrich), 10 μg/ml insulin (I-1882, Sigma-Aldrich), and 1% penicillin and streptomycin
(PenStrep; 100X; 15070–063, GIBCOby Life Technologies). All cells were cultured in the
atmosphere of 5% CO2 at 37°C.
Plasmid DNA and cell transient transfection
Gene expression construct forMYO1C (TrueORF cDNA clones and PrecisionShuttle vector
system, SC 315975) and a corresponding empty vector, pCMV6-XL5 (PS100020) were pur-
chased fromOriGene Technologies, USA. Bacterial transformation was performed using
Escherichia coli as host (E. Coli, NovaBlue Singles Competent Cells, Novagen by Merck KGaA,
Germany). Midiprep Kit (Qiagen, USA) was used for plasmid purification.
Transient transfectionwas performedusing Lipofectamine 2000 (11668019, Invitrogen by
Life Technologies) prepared in Opti-MEM I reduced serummedium (11058, GIBCOby Life
Technologies). Cells were transfectedwith four different mixtures ofMYO1C gene expression
construct and the corresponding empty vector so that all cells always received a maximum of
0.9 μg/ml external DNA. The four different gene construct concentrations were prepared as fol-
lows: 0.9 μg/ml empty vector + 0.0 μg/mlMYO1C-construct, 0.6 μg/ml empty vector + 0.3 μg/ml
MYO1C-construct, 0.3 μg/ml empty vector + 0.6 μg/mlMYO1C-construct, and 0.0 μg/ml empty
vector + 0.9 μg/mlMYO1C-construct.
For cell proliferation assays, the final ratio of total plasmid DNA to Lipofectamine 2000 was
0.09 μg to 0.45 μl per well of 96-well plate (167008, Nunc by Thermo Scientific); for protein
expression analyses, 3 μg to 10 μl per well of 6-well plate (140675, Nunc by Thermo Scientific)
and 6 μg to 15 μl in 60-mm petri dish format (150288, Nunc by Thermo Scientific).
siRNA transfections for gene knockdown studies
siRNA duplexes (MYO1CHSS106886) forMYO1C knockdown and corresponding scrambled
siRNA duplexes (mediumGC contents, 12935–300) as the negative control were purchased
from Invitrogen by Life Technologies. siRNA duplexes forMYO1C were sense: 5’-CCUAUCG
CCGCAAAUACGAAGCUUU-3’, antisense: 5’-AAAGCUUCGUAUUU-GCGGCGAUAG
G-3’. siRNA transfections forMYO1C knockdownwere performed using LipofectamineRNAi-
MAX (1378–075, Invitrogen by Life Technologies) in Opti-MEM I reduced serummedium as
describedby the manufacturer.
For cell migration assay, SMARTpool siGENOME siRNA for MYO1C (M-015121-0005)
and siGENOMENon-Targeting siRNA Pools (D-001206-14-05) were purchased from Dhar-
macon by Thermo Scientific,USA. The pool of siRNA forMYO1C contains 1) sense: 5’-GGCU
ACAAGCCAGAAGAGUAC-3’, 2) sense: 5’-UCAGUUACCTCCT GGAAAAG-U-3’, and 3)
sense: 5’-GCUCAAAGAAUCCCAUUAUGA-3’. siRNA-transfection was performed using
DharmaFECT1 (Thermo Scientific,USA) as described by the manufacturer.
Cell proliferation assay
The effects of over-expression and knockdown ofMYO1C on proliferation was performed in
HEK-293 and MCF10A cells, respectively. The final concentration ofMYO1C-construct used
in the over-expression experiment was mentioned earlier; the final concentration forMYO1C-
siRNA in the knockdown experiment for cell proliferation assay was 10nM per well. Results
from these assays were analyzed using 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium compound or the so-called colorimetricMTS-based assay. In
brief, cells were seeded into 96-well plate at 1x104 cells per well for HEK-293 or 0.75x104 cells
per well for MCF10A and were subjected to transfections. At different time points post trans-
fection (24, 48, 72 or 96 hours), 20 μl of the CellTiter 96 AQueous One Solution (G3582,
Functional Analysis of the Tumor Suppressor Candidate MYO1C
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Promega, USA) was added into each well containing 100 μl of growth medium, cells were incu-
bated for 2.5 hours and the quantity of metabolized formazan, which is directly proportional to
the number of living cells in culture, was measured by 490 nm-absorbance and recorded using
Mithras LB940 (BertholdTechnologies, BadWildbad, Germany) with the programMikroWin
v.4.31 (Mikrotek Laborsystems, Overath, Germany). At least three independent experiments,
each in quadruplicates, were performed.
Cell migration assays
MCF10A cells were seeded in 6-well plates and transfected after 24 hours with either scrambled
siRNA, serving as a control, or Dharmacon siRNA forMYO1C (M-015121-005, Thermo Scien-
tific) to a final concentration of 20 μM (as recommended by the manufacturer) using Dharma-
FECT1 (Thermo Scientific).After incubation for 24 hours, cells were trypsinized, counted,
diluted to 2x105 cells per ml and incubated with 2.5 μM DiI-C16 (Molecular Probes, Invitro-
gen) for 30 min at 37°C, washed and 4x104 cells per well were plated in the OrisTMCell Migra-
tion Assay plates (Platypus Technologies) containing cell seeding stopper. Cells were allowed
to attach and spread overnight at 37°C before the stoppers were removed and mediumwas
refreshed.Migration was measured in real time using the POLARstar Omega plate reader
(BMG LABTECH,Germany) with temperature at 37°C and 5% CO2 collecting data points
every 20 min for up to 24 hours. Migration speed was measured by calculating the area under
the curve for each well. Pictures were taken before and after the migration assays. Each treat-
ment was done in triplicate.
Continuous real-time cell analysis (RTCA) assay
The xCELLigence RTCA system (Roche Applied Science, Germany) is a quantitative assay
that monitors changes in cell adhesion, spreading, morphology, and growth in real time.
The system records electrical signals that denote cell impedance to the electrodes in each
well and translates the signals to ‘cell index’ values, representing degree and intensity of cell
adhesion, morphology, and growth. We used this system to examine cell adhesion and
spreading of the MCF10A cells after knockdown ofMYO1C as well as to examine a potential
dose-dependent response toMYO1C depletion. The experimental setup included seeding
5,000 cells per well in 50 μl of growth media without antibiotic in microtiter E-plates (Roche
Applied Science). Different mixtures ofMYO1C-siRNA and scrambled siRNA were pre-
pared in Lipofectamine RNAiMAX and Opti-MEM I reduced serummedium to yield final
concentrations of 1, 3, 5, 10, 15 or 20 nM ofMYO1C-siRNA and 50 μl of each mixture was
added to wells containing 5,000 MCF10A cells. Western blot analysis of MYO1C protein
levels at time point 48 post transfection showed concentrations 10, 15 and 20 nM of
MYO1C-siRNA resulted in 90–95%MYO1C knock down, whereas concentrations 1, 3 and
5 nM ofMYO1C-siRNA resulted in 75–80%MYO1C protein level reductions (data not
shown). Accordingly, and to detect potential dose-dependent effects ofMYO1C depletion
on cell phenotypes as screened by the xCELLigence RTCA system, four different mixtures of
MYO1C-siRNA and scrambled siRNA prepared in Lipofectamine RNAiMAX and Opti-
MEM I reduced serummedium to yield final concentrations of 1, 3, 5, or 10 nM were used.
Control wells received only 50 μl of the mock-transfectingmixture. The plates were placed
onto the RTCA station in a humidified incubator at 37°C in which the cell index values per
well were recorded every 15 min up to 72 hours. For each of theMYO1C-siRNA concentra-
tions, mean values and standard error of the mean (SEM) were derived from six indepen-
dent repeats.
Functional Analysis of the Tumor Suppressor Candidate MYO1C
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Serum activation assay
HeLa cells were seeded in 6-well plates and transfected the next day with either scrambled
siRNA, serving as a control, or siRNA forMYO1C to a final concentration of 30 nM. After 48
hours’ incubation, the media were substituted with 2.5 ml per well newmedia without serum
and antibiotics (PenStep), followed by incubation for another 24 hours. Subsequently, 500 μl
serumwas added into each well and cells were harvested and lyzed for protein extraction after
2, 5 and 20 min post serum activation. Three independent experiments were performed.
Real-Time PCR (RT-PCR)
To verify the efficiencyof knockdown of the siRNA againstMYO1C in cell migration assays,
RT-PCR was performed. RNA was isolated from cells using the RNeasy kit (74104, Qiagen,
USA) and cDNA was made using the Taqman Reverse Transcription kit (4366596, Applied
Biosystems by Life Technologies). RT-PCR was performed using probes from Universal Probe-
Library (04683633001, Hoffmann-La Roche, Switzerland). Amplification and analysis was per-
formed on an ABI 7900 (Applied Biosystems).
SDS-PAGE and Western blotting
Cell lysates were prepared using supplemented RIPA buffer (89901, Thermo Scientific) and the
protein concentrations were measured by Bradford protein assay (Bio-Rad Protein Assay Dye
Reagent Concentrate 500–006, Bio-Rad Laboratories, USA) at 600 nm (Novaspec II, Bio-
chrome, UK).
For Western blot, cell lysates containing 20 μg protein were denatured and resolved in pre-
cast SDS-PAGE (NuPAGE 4–12% Bis-Tris gel, Invitrogen by Life Technologies). Gels were
transferred using the iBlot system (IB3010-01; iBlot Transfer Stack, Regular-Nitrocellulose-
and IB1001EU iBlot Gel Transfer Device, Invitrogen by Life Technologies). After fixation,
membranes were blocked with 5% non-fat drymilk in TBST buffer at room temperature for 1
hour and immunoblotted by incubation with different optimized dilutions of monoclonal or
polyclonal primary antibodies (Table 1). Secondary antibodies were horseradish peroxidase
conjugated goat anti-rabbit IgG (H+L) (111-001-003) or goat anti-mouse IgG (H+L) (115-035-
062, Jackson ImmunoResearch Laboratories, Inc., USA). Membranes were incubated in Super-
SignalWest Pico (34080) or Femto (34096) Chemiluminescent Substrate (1:1 mixture of Lumi-
nol/Enhancer and Stable Peroxide Buffer; Thermo Scientific Inc.) solutions 5 min prior to
detection. Chemiluminescense signals were recorded with a LAS1000 camera (Luminescent
Image Analyzer, LAS1000 Plus, Fuji-Film, Japan) using the Image Reader LAS1000 V2.6 pro-
gram.Western blots were performed in independent triplicates for each experiment. Immuno-
blotting signals were quantified by ImageJ (http://rsbweb.nih.gov/ij) and protein levels were
calculated as relative protein level normalized against Gapdh.
Western blot analysis of PI3K/AKT and RAS/ERK pathways
Onemillion HeLa cells were seeded in 60-mm petri dish format for 24 hours prior to the trans-
fection. Cells were transfected with a total of 0.9 μg/ml of four different mixtures of the empty
vector andMYO1C-construct, as described earlier, to produce final concentrations ofMYO1C-
construct (0.0, 0.3, 0.6 or 0.9 μg/ml) to investigate potential MYO1C dose-dependent effects in
the present experimental setup. Cell lysates were prepared at 24 hours post transfection and
subjected to Western blot analysis for MYO1C protein as well as 10 key components of the
PI3K/AKT pathway (AKT, pAKTS473, pAKTT308, IRS-1, PTEN, 14-3-3β, p85, p110α, p110β,
p110δ, Table 1) and three downstream proteins of the RAS/ERK signaling pathway (RAS, ERK
Functional Analysis of the Tumor Suppressor Candidate MYO1C
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and pERK). Information on the manufacturers from which the antibody orders were made as
well as antibody dilutions used in the experiments are presented in Table 1.
Statistical analysis
The statistical analysis software SPSS (Statistical Package for the Social Sciences; IBM SPSS
Data Collection) version 21 was used. The data are presented as mean ± SEM (standard error
of the mean). A probability value less than 0.05 were regarded as statistically significant.
Results
Protein levels of MYO1C was significantly lower in poorly differentiated
endometrial carcinomas
Immunohistochemical analysis of a panel of 62 endometrial carcinomas (19 highly differenti-
ated stage I tumors, 24 moderately differentiated stage II tumors, 19 poorly differentiated stage
III tumors) and 10 endometrial hyperplasias revealed a significant association between
MYO1C protein level and tumor grade (P = 0.035, linear-by-linear association in the SPSS chi-
square test). In this analysis, we found that the proportion of samples with high level of
MYO1C protein was highest in hyperplasias (60%) and lowest in stage III tumors (11%),
whereas the proportion of tumors with low MYO1C protein level was lowest in hyperplasias
(10%) and highest in stage III tumors (47%) (Fig 2B). Pairwise differences between sample
groups were not significant; however, when the MYO1C protein level pattern in all tumors as a
group (n = 62) were compared with hyperplasia samples (n = 10), the Fisher’s exact test analy-
sis showed a statistically significant association (P = 0.0303) between groups of samples and
levels of MYO1C (Fig 2C), indicating that the amount of MYO1C protein was significantly
lower in endometrial carcinomas compared to hyperplasia.
Table 1. List of primary antibodies and the optimized dilution.
Antibody Dilution Product number, Manufacturer
rabbit anti-AKT 1:500 • sc-8312, Santa Cruz Biotechnology
• 9272, Cell Signaling Technology
rabbit anti-pAKTS473 1:500 sc-7985, Santa Cruz Biotechnology
rabbit anti-pAKTT308 1:500 • sc-16646, Santa Cruz Biotechnology
• 4056, Cell Signaling Technology
rabbit anti-IRS-1 1:500 sc-7200, Santa Cruz Biotechnology
rabbit anti-MYO1C 1:600 HPA001768, Sigma-Aldrich
rabbit anti-ERK1/2 1:800 9102, Cell Signaling Technology
rabbit anti-phosphorylatedERK1/2 1:800 9101, Cell Signaling Technology
mouse anti-PTEN 1:500 sc-7974, Santa Cruz Biotechnology
mouse anti-RAS 1:200 80–1735, Assay Designs and Stressgen
rabbit anti-14-3-3β 1:500 sc-628, Santa Cruz Biotechnology
rabbit anti-GAPDH 1:500 to 1:1000 sc-25778, Santa Cruz Biotechnology
rabbit anti-p110α 1:500 • sc-7174, Santa Cruz Biotechnology
• 4249, Cell Signaling Technology
rabbit anti-p110β 1:500 • sc-603, Santa Cruz Biotechnology
• 3011, Cell Signaling Technology
rabbit anti-p110δ 1:500 sc-7176, Santa Cruz Biotechnology
mouse anti-p110δ 1:1000 p75220, BD Transduction Laboratories
rabbit anti-p85 1:500 1:1000 • sc-423, Santa Cruz Biotechnology
• Q63787, Millipore
doi:10.1371/journal.pone.0164063.t001
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Over-expression of MYO1C resulted in significant decrease in cell
proliferation
Using western blot, a panel of human cell lines, including embryonic non-cancerous HEK-293,
adult non-cancerous MCF10A and adult cancerous HeLa cell lines were screened for de novo
MYO1C protein expression (Fig 1). The choice for these cell lines was based on the feasibility
of performing cell transfection experiments with these cells as well as to ensure different cell
types (adult, embryonic, cancerous and normal cells) are tested. Cell lines with low (HEK-293
and HeLa) and medium to high (MCF10A) de novoMYO1C protein levels were selected for
gene expression or knockdown experiments, respectively, to assess the effect of MYO1C on the
cell proliferation. HEK-293 cells with low de novoMYO1C protein level were transfected with
0.0, 0.3, 0.6, or 0.9 μg/ml of theMYO1C gene expression construct (hereafterMYO1C-con-
struct). The transfected cells were monitored for MYO1C protein level as well as for the num-
ber of live cells at 24, 48, 72 and 96 hours post transfection.Western blot showed a correlation
between the amount ofMYO1C-construct used in the cell transfection experiments and the
levels of MYO1C protein in the cells (Fig 3A). Over-expression of MYO1C protein in the cells
transfected withMYO1C-construct was observed at 24 hours and reached to its highest expres-
sion capacity after 48 hours (Fig 3B).
MTS-based cell proliferation assay was used to screen the number of live cells 48 hours after
transfectionwith increasing amounts ofMYO1C-construct (0.0, 0.3, 0.6 or 0.9 μg/ml), hence
expressing increasing amount of MYO1C (Fig 3A). The analysis revealed a dose-dependent
negative correlation between the amount ofMYO1C-construct used in cell transfections and
the number of live cells (Fig 3B). This dose-dependent and negative correlation reached a
Fig 2. Protein levels of MYO1C in endometrial hyperplasia and endometrial adenocarcinomas of
stage I-III. a) Representative images for the IHC staining of MYO1C in tissue samples of endometrial
carcinoma with low, medium and high MYUO1C protein levels. b) Significant association was found between
MYO1C protein level and tumor grade (P = 0.035, linear-by-linear association in the SPSS chi-square test).
The proportion of samples with high MYO1C protein level was greatest in hyperplasias (Hyp) and smallest in
stage III tumors, whereas the proportion of tumors with low abundance of MYOC1 was smallest in
hyperplasias and highest in stage III tumors. Pairwise differences between sample groups were not
significant. c) When the samples were regrouped as tumors and hyperplasia, the Fisher’s exact test showed
significant difference in MYO1C expression between these two groups of samples (P = 0.0303).
doi:10.1371/journal.pone.0164063.g002
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significant level (P< 0.05) between the control cells (received 0.0 μg/mlMYO1C-construct)
and those transfected with the highest concentration (0.9 μg/ml) of theMYO1C-construct (Fig
3B).
Based on results from this screening experiment, and to ensure cells express enough amount
of MYO1C protein to produce significant effects, we chose the concentration 0.9 μg/ml
MYO1C-construct for the cell proliferation assays. Cells were transfected with 0.9 μg/ml of
MYO1C-construct or the empty vector and were monitored for the number of live cells and
protein level of MYO1C at 24, 48, 72 and 96 hours post transfections.Western blot analysis
revealed successful expression of MYO1C protein following gene construct transfection in the
cells at 24 hours, reaching its highest capacity after 48 hours (Fig 3C). The analysis revealed a
strong response in the cells to MYO1C over-expression in form of a highly significant
(P< 0.001) decrease in the number of live cells starting at 48 hours post transfection and
throughout the experiment time span (Fig 3D).
MYO1C-siRNA treatment resulted in significant increased cell
proliferation
We next aimed to confirm the observed effect ofMYO1C expression on reduced number of
live cells in a reciprocal experimental design using aMYO1CmRNA silencing approach. For
this experiment we used normal breast epithelial MCF10A cells with high de novoMYO1C
protein levels, as identified by the initialWestern blot screening of human cell lines (Fig 1).
Fig 3. Over-expression of MYO1C significantly decreased viability of HEK-293 cells. (a) Immunoblot of MYO1C proteins in HEK-293 cells
shows increased expression in the cells transfected with different amounts of MYO1C-construct at 48 hours post-transfection in comparison
with the cells transfected with corresponding empty plasmid, serving as control. The image is a representative from at least three independent
experiments. (b) Dose-response effect of over-expression of MYO1C protein on cell proliferation was observed at 48 hours post-transfection in
comparison with cells transfected with empty vector. Each bar represents mean value ± SEM of all repeats, a Student’s t-test was used to
compare the differences in mean values, *P-value < 0.05 versus the corresponding empty plasmid. (c) Immunoblot of MYO1C proteins in HEK-
293 cells shows increased expression in MYO1C-transfected cells at 24, 48, 72 and 96 hours post-transfection. The image is a representative
from at least three independent experiments. (d) Relative number of living cells was reduced in MYO1C-transfected cells. Significant decline
was observed at 48, 72 and 96 hours post-transfection compared to cells transfected with the empty vector. Each bar represents mean value ±
SEM of all repeats (at least three independent experiments, each in quadruplicates). A Student’s t-test was used to compare the differences in
mean values, ****P-value < 0.001 versus the corresponding empty plasmid.
doi:10.1371/journal.pone.0164063.g003
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MCF10A cells were transfected with 10 nMMYO1C-specific siRNA or scrambled siRNA fol-
lowed by MTS-based cell proliferation screening at 24, 48, 72 and 96 hours post transfections.
Western blot analysis revealed successful reduction in MYO1C protein levels in theMYO1C-
siRNA transfected cells with the maximal effect (over 90% suppression) at 72 and 96 hours
post-transfection compared to cells that received scrambled siRNA (Fig 4A).MYO1C-siRNA
cell proliferation assays indicated again a strong negative correlation between the level of
MYO1C protein expressed and the number of live cells. This negative correlation became
highly significant (P< 0.001) at 48, 72 and 96 hour time points post transfection compared to
untreated cells (time point zero, Fig 4B).
Fig 4. siRNA-knockdown of MYO1C enhanced viability. (a) Immunoblot of MYO1C protein expression in
MCF10A cells transfected with MYO1C-siRNA and negative control (scrambled siRNA) to the final
concentration of 10nM at 24, 48, 72 and 96 hours post-transfection. The image is a representative from at
least three independent experiments. (b) Histogram showing percentages of relative cell viability of MCF10A
cells transfected with MYO1C-siRNA and scrambled siRNA to the final concentration of 10nM. Significant
increase in the number of live cells was observed at 48, 72 and 96 hours post-transfection compared to cells
transfected with the scrambled siRNA. Each bar represents mean value ± SEM of all repeats (at least three
independent experiments, each in quadruplicates). A Student’s t-test was used to compare the differences in
mean value, ****P-value < 0.001 versus cells treated with scrambled siRNA as well as untreated cells (time
point zero).
doi:10.1371/journal.pone.0164063.g004
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Reduced MYO1C expression impaired cell migration, cell spreading and
cell adhesion
To investigate the potential effect ofMYO1C on cell migration, cell spreading and cell adhe-
sion, we usedMYO1C-siRNA treatment in two independent experimental setups: the gap clo-
sure assay and xCELLigenceRTCA system.
MCF10A cells with high de novo protein expression of MYO1C were transfected with 20
nM ofMYO1C-siRNA or scrambled siRNA (efficiencyof siRNA treatment was first controlled
by RT-PCR, Fig 5A) and the cells were subjected to the gap closure assay. In this assay, cells are
allowed to attach to the plate containing a cell seeding stopper and spread overnight, a gap in
the well is created by removing the cell seeding stopper, cells are allowed for another 24 hours
Fig 5. Decrease in cell migration and adhesion of MCF10A cells after knockdown of MYO1C. (a) The expression levels of MYO1C in
the MCF10A cells subjected to 20 nM siRNA transfection were verified with RT-PCR. (b) Geometry on gap immediately after ripping of the
stopper (I) and geometry on gap of the control (scrambled siRNA) (II), and MYO1C-siRNA transfected (III) after 24-hour incubation were
shown. The white circles show the area of the geometry on gap at each measurement. (c) The analyses of the geometry on gap closure
(migration assay) of MCF10A cells transfected with MYO1C-specific siRNA was evaluated after ripping off cell seeding stopper followed by
24-hour incubation in comparison to the geometry of control cells. (d) Immunoblot of MYO1C protein levels in MCF10A cells transiently
transfected with different concentrations of MYO1C-siRNA (1, 3, 5 and 10 nM) and control (mock transfection) at 48 hours post-transfection.
(e) Histogram showing percentages of relative cell index of MCF10A cells transfected with MYO1C-siRNA and control cells (received mock
transfection). A dose-dependent decrease in relative cell index response to MYO1C depletion was observed reaching to a significant value
with concentrations of 5 and 10 nM of MYO1C-siRNA at 48 hours post-transfection compared to control cells (mock transfection). Images
shown in (b) and (d) are representatives from three and six independent experiments, respectively. Each bar in (a), (c) and (e) represents
the mean value ± SEM from three and six independent experiments, respectively. A Student’s t-test was used to compare the differences in
mean value, *P-value < 0.05, ***P-value < 0.005 and ****P-value < 0.001 versus control cells.
doi:10.1371/journal.pone.0164063.g005
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to move into the gap to fill the empty space and a plate reader measures the geometry of the
gap in real time (Fig 5B). The analyses revealed that MCF10A cells transfected withMYO1C-
siRNA, hence with significant diminished expression ofMYO1C, were significantly slower in
moving and closing the produced gap compared to the control cells (Fig 5C).
In another set of experiments, we used the xCELLigenceRTCA system to monitor for the
potential alteration in the adhesion and spreading capacity of MCF10A cells in response to dif-
ferent concentrations ofMYO1C-siRNA treatment. This experiment was performed to address
three research questions: to verify results from the gap closure assay, to investigate whether the
observed impaired cell mobility in response toMYO1C depletion in gap closure assay is due to
impaired cell adhesion and spreading, and to examine whether the response toMYO1C deple-
tion follows a dose-dependent pattern. The RTCA assay is a highly sensitive and quantitative
system that provides a continuous (real-time) cell monitoring system in which the electrode
impedance to the cell mobility and adherence is measured and displayed as a cell index. The
impedance is dependent on the number of cells as well as the intensity of interaction of cells
with the electrodes, reflected by the ability of cells to proliferate and to adhere to the surface of
electrodes, respectively.
After an initial screening experiment,MCF10A cells were transfected with 1, 3, 5, or 10 nM
ofMYO1C-siRNA and cells were subjected to analysis with the RTCA system every 15 min for
up to 72 hours. The efficiencyof the treatment was verified by Western blot at 48 hours post
transfection showing a linear correlation betweenMYO1C-siRNA concentration and MYO1C
protein depletion (from 75% to over 90% depletion, Fig 5D). The analysis revealed lowered
expression of MYO1C resulted in diminished cell indexes and this reduction was suggested to
be dose-dependent as it reached a significant level (P< 0.05) for the concentration 5.0 nM
treatment and a highly significant (P< 0.001) for the concentration 10.0 nM treatment com-
pared to the control cells treated with the mock transfection (Fig 5E).
Over-expression of MYO1C protein resulted in higher p110α protein
levels, and decreased PTEN, AKT and pAKT levels
To investigate the potential involvement ofMYO1C in the PI3K/AKT and RAS/ERK signal-
ing pathways, we examined potential alterations of eight key components of the PI3K/AKT
signaling pathway (AKT, pAKTS473, pAKTT308, IRS-1, PTEN, 14-3-3β, p85, p110α/β/δ) and
three downstream components of the RAS/ERK signaling pathway (RAS, ERK and pERK)
in response to induced over-expression of MYO1C protein in cells transfected with the
MYO1C-construct. Cells were transfected with four different concentrations (0.0, 0.3, 0.6 or
0.9 μg/ml) ofMYO1C-construct, cell lysates were prepared at 24 hours post transfections
and subjected to Western blot analysis to investigate potential dose-dependent effect of
MYO1C over-expression on expression, stabilization and/or activation of these proteins.
The analysis revealed a dose-dependent response to MYO1C over-expression in the cells
that reached its maximum in response to 0.9 μg/mlMYO1C-construct transfection as fol-
lows (Fig 6A and 6B):
• Significant decrease in the expression levels of the total AKT protein (P< 0.0001) and both
of its phosphorylated forms (pAKTS473, pAKTT308) (P< 0.05 and P< 0.05).
• Significant decrease in the expression level of the PTEN protein (P< 0.001).
• Significant increase (P< 0.0001) in the p110α protein level.
• No significant change in the expression level/activation of the remaining seven proteins was
detected.
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Decreased MYO1C expression allowed fast serum-induced activation of
AKT
We next investigated potential effect of depletion of MYO1C protein (Fig 7A) on serum-induced
activation (phosphorylation) of AKT and ERK in the cells treated with increasing amount of
MYO1C-siRNA. This experimentwas designedwith a double goal: 1- to confirm and verify the
observednegative correlation between theMYO1C protein level and phosphorylation of AKT
(Fig 6) and 2- to clarify whether the observed lowered level of pAKTS473 in response to over-
expression of MYO1C (as presented in Fig 6) was a natural consequence of decreased expression
level of AKT or was rather a specific response to theMYO1C over-expression.
Cells transfectedwith different concentrations ofMYO1C-siRNA or scrambled siRNA were
serum starved for 24 hours, serumwas added to the cell cultures and at 2 min, 5 min and 20 min
after addition of serum, levels of pAKT and pERK in the cell lysates were examined. The analysis
showed a very low level of pAKTS473 in both cells transfectedwithMYO1C-siRNA or scrambled
siRNA (control) after 24-hour serum starvation. Following serum stimulation, in cells transfected
withMYO1C-siRNA it was found that AKTwas rapidly (within 2 min) phosphorylated in its resi-
due S473 (pAKTS473), whereas in the control cells transfectedwith scrambled siRNA this effect
was significantly less (Fig 7B). Interestingly, the pattern of serum-inducedAKT activation
appeared to be completely different between theMYO1C-siRNA transfected cells and the scram-
bled siRNA-transfected control cells: in the control cells the level of pAKTS473 slowly, but stably
increased,whereas in theMYO1C-siRNA treated cells there was a fast (at 2 min) and significantly
strong AKT activation response to the serum stimulation that over the time went in the other
direction and reached a significant reduced level at 20 min post serum stimulation (Fig 7B). No
significant correlation between the expression level of MYO1C and phosphorylation of ERK,
before and after serum treatment, was detected (Fig 7C).
Discussion
In the year 2000, Hanahan andWeinberg proposed six hallmarks of cancer (revised later to
eight hallmarks); eight traits that are required for a cell to evolve from normal to tumor: ability
Fig 6. Increased expression of MYO1C protein affects expression of PI3K/AKT components. (a) The immunoblot of proteins
from cell lysates of the HeLa cells transfected with serial dilution of MYO1C-gene expression constructs and (b) derived relative
protein expressions in response to serial transfection of MYO1C that showed a decreasing in AKT, pAKTS473, pAKTT308 and PTEN
at the maximal dose but increasing in p110α protein expression in comparison with cells transfected with empty construct (control);
each bar represents mean value (± SEM), a Student’s t-test was used to compare the differences in mean value, *P-value < 0.05,
***P-value < 0.005 and ****P-value < 0.001 versus control cells. The images shown are representative of Western blotting from at
least three independent experiments.
doi:10.1371/journal.pone.0164063.g006
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to sustain proliferative signaling, ability to evade growth suppressors, ability to avoid apoptosis,
ability to induce angiogenesis, ability to replicate immortally, ability to avoid immune destruc-
tion, ability to deregulate cellular energetics, and ability to invade and metastasize [37, 38]. In
the present work, by using clinical samples along with cell culture-based functional assays, we
aimed to examine the original hypothesis ofMYO1C acting as a tumor suppressor gene [6] in
relation to some of Hanahan andWeinberg’s proposed tumorigenesis abilities.
We examined levels of MYO1C protein in a panel of well-stratified endometrial carcinomas
and found a significant negative association (P = 0.035) between the level of MYO1C protein
expression in hyperplasia and stage III tumors (Fig 2). Pairwise analysis of differences between
stage I, II and III sample groups did not reach significant values, indicating that lowered pro-
tein level of MYO1C is equally important in all tumor stages. We also found significant
(P = 0.0303) association comparing sample type (tumor vs hyperplasia) and MYO1C protein
level, indicating that the level of MYO1C protein is significantly lower in tumors compared to
hyperplasia samples. In conclusion, our analysis revealed a significant association between low-
eredMYO1C protein level and endometrial carcinogenesis and also indicated that reduced
MYO1C levels is equally important in early as well as late tumor stages, suggesting an impor-
tant role for MYO1C in all stages of endometrial carcinogenesis.
We then performed cell transfection experiments withMYO1C-over expression constructs
orMYO1C-siRNA to over-express or knockdownMYO1C protein in the cells, respectively, fol-
lowed by cell proliferation assays. Our analysis revealed that cells expressing extra MYO1C
protein had a diminished cell proliferation capacity (Fig 3). This finding was amply validated
Fig 7. Fast activation of AKT in response to serum activation after knockdown of MYO1C in HeLa cells. (a) The
immunoblot of proteins from cell lysates of the HeLa cells transfected with MYO1C-siRNA in comparison with non-transfected
HeLa cells and subjected to serum activation for 2, 5 and 20 minutes. Histogram showing percentages of relative protein
expression of pAKTS473 (b) and pERK (c) from HeLa cells after serum supplement for 2, 5 and 20 minutes. The expression of
pAKTS473 was significantly higher after serum supplement at 2 minutes and significantly lower after 20 minutes in comparison to
control cells (scrambled siRNA); there was no significant difference in activation of ERK. Each bar in (b) and (b) represents the
mean value ± SEM for at least three independent repeats. A Student’s t-test was used to compare the differences in mean value,
*P-value < 0.05 versus control cells. The images shown are representative of Western blotting and serum activation assay from at
least three independent experiments.
doi:10.1371/journal.pone.0164063.g007
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in a reverse experiment design in whichMYO1C gene expression was knocked down using
siRNA, where we detected a significant correlation between reducedMYO1C protein level and
increased number of viable cells (Fig 4). Taken together, these experiments suggest a significant
role for the MYO1C protein in cell proliferation, presumably through regulation of one of or a
combination of the first three of Hanahan andWeinberg’s proposed tumorous traits: ability to
sustain proliferative signaling, ability to evade growth suppressors, and/or ability to avoid apo-
ptosis [37, 38].
The tumorous trait of “ability to evade growth suppressors” can be reached through
impaired cell adhesion/cell spreading-mediated contact inhibition [39] and/or becoming irre-
sponsive to cell proliferation regulationmechanisms [40, 41]. Accordingly, we next aimed to
examine the potential role of MYO1C protein in cell adhesion, spreading and migration.We
performed two independent cell migration/cell adhesion/cell spreading experiments, the
OrisTMCellMigration Assay (gap closure assay) and the xCELLigenceReal-Time Cell Ana-
lyzer (RTCA) system, for cells in whichMYO1C expression was effectively knocked down
using the siRNA technology (Fig 5A). These parallel experiments jointly confirmed that reduc-
tion in MYO1C protein resulted in a significant reduced ability of the cells to adhere to the sur-
face, spread and therefore to migrate (Fig 5B–5D). Cells characteristically can spread on an
extracellularmatrix by extendingmembrane protrusions such as membrane ruffles, and can
adhere to other cells and their surrounding stroma via specific contact sites known as focal
adhesions [42]. The contact with the surrounding cells, matrix and surfaces is one of the limit-
ing factors that determine how and to what extent a normal cell can grow and divide. In fact
loss of “contact inhibition” is recognized as one of the strategies adapted by the tumorous cells
towards acquiring the “ability to evade growth suppressors” [37, 38]. Moreover, repetition of
cycles of cell spreading and adhesion processes on opposing sides of a cell forms the basis for
cellular migration [43], which in turn relies on lipid rafts [44]. The lipid raft’s role in this con-
text is to concentrate the signalingmolecules necessary for migration/spreading on the cell sur-
face, thereby efficiently and rapidly promoting the corresponding signal transductions [45]. It
has been shown that MYO1C specifically and tightly binds to PI(4,5)P2 (PIP2) [17, 18], is spa-
tially associated with lipid rafts [19], is involved in regulation of lipid raft recycling, and there-
fore may contribute to signaling pathways underlying cell migration and spreading. Using the
Cell Tracker CMRA system combined with velocity tracking software analysis, Brandstaetter
et al. (2012) showed that knockdown of MYO1C dramatically reduces cell spreading and
causes a reduction in lipid raft markers at the cell surface of spreading HeLa cells. MYO1C
knockdown also resulted in the redistribution of focal adhesions, as well as in a reduction in
the migration speed and track length of migrating cells [19, 46]. Here we report a similar obser-
vation, but using different methodologies and a different cell line (MCF10A). Taken together,
in the present work we provided additional evidence for potential contribution of tumor sup-
pressor candidate MYO1C to mechanism/s involved in cell adhesion, spreading and migration,
confirming and extending the earlier findings. Here we hypothesize that reduced expression of
tumor protein MYO1C results in impaired cell adhesion and cell spreading-mediated contact
inhibition, and therefore in induced tumorous phenotype.
Several reports indicate a role for MYO1C in the glucose uptake into adipocyte and muscle
cells through insulin-induced tethering of glucose transporter 4 (GLUT4) vesicles [12, 23, 47,
48] potentially through the PI3K/AKT signaling pathway [49]. Beside glucose homeostasis, the
PI3K/AKT signaling is known as one of the main signaling pathways involved in cell survival,
proliferation and apoptosis, and thus contributes to cancer development. In the present work
we aimed to investigate the potential interplay betweenMYO1C and expression and/or activa-
tion of components of the PI3K/AKT signaling pathway.
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When cells were transfected with a gene expressionMYO1C-construct, inWestern blot
analysis of the transfected cells for 11 components from PI3K/AKT and RAS/ERK signaling
pathways, we detected significant increase in the expression level of p110α protein, significant
decrease in the expression level of the PTEN protein and in the expression levels of the total
AKT protein as well as both of its phosphorylated forms (Fig 6A and 6B). Our analysis pro-
vided evidence for a potential interplay betweenMYO1C and PI3K/AKT signaling in cells that
are not stimulated.
Catalytic subunits of PI3K play a critical role in growth factor signaling and survival by
phosphorylating inositol lipids. Gain of functionmutations in the PIK3CA gene (encoding
p110α) has been found to be oncogenic and is implicated in cervical cancers [50]. It is shown
that p110α is involved in the activation of AKT upon stimulation by receptor tyrosine kinases
ligands such as EGF, insulin, IGF-1, VEGFA and PDGF [51, 52]. In the present work we found
a significant positive correlation between levels of MYO1C and p110α in cells that were not
stimulated. Accordingly, the observed level of p110α in the cells is not reflecting the activation
status of PI3K/AKT signaling, but could reflect a potential involvement of MYO1C in PIK3CA
gene expression. An alternative explanation for the observed effect could be a protective feed-
back mechanism in response to MYO1C-induced PI3K/AKT suppression, in response to
which cells produce excess of p110α to be able upon growth factor stimulation to rapidly coun-
teract MYO1C function.
Among PtdIns(3,4,5)P3 phosphatases, PTEN (phosphatase and tensin homologue deleted
on chromosome 10) has long been identified as a haploinsufficient tumor suppressor gene and
negative regulator of the insulin signaling via PI3K/AKT signaling by dephosphorylating PIP3
[53, 54]. Expression of PTEN inhibits PI3K signaling through rapid decrease of elevated insu-
lin-induced PtdIns(3,4,5)P3 levels, thus inhibiting the phosphorylation of downstream targets
such as AKT [55]. Here we found that in response to excess expression of MYO1C, the level of
PTEN protein was reduced in the cell. However, as cells were at resting (not stimulated) state,
we hypothesize that the observed effect could be a gene expression feedback system, i.e. in the
presence of MYO1C, there is less need for the PI3K/AKTmodulating PTEN protein, hence
PTEN gene expression has become down-regulated.
In the MYO1C over-expression experiments, we additionally detected a strong and signifi-
cant negative correlation between protein levels of MYO1C and AKT and also a weaker nega-
tive correlation, but still significant, between levels of MYO1C and pAKTS473 and pAKTT308
(Fig 6B). As the cells were not stimulated in this experiment, the negative correlation between
MYO1C expression and levels of pAKTS473 and pAKTT308 reflects a potential inhibitory role
for MYO1C protein on expression as well as activation of AKT. As in this experiment a very
strong negative correlation betweenMYO1C and AKT protein levels was detected, this raised
the question whether the detected reduced levels of pAKTS473 and pAKTT308 were a direct out-
come of reduced expression of AKT protein, rather than MYO1C inhibitory function on AKT
activation. To address this, we performed serum starvation/stimulation experiments to exam-
ine the dynamic of AKT activation in response toMYO1C-siRNA treatment. In this experi-
ment we observed a significantly stronger and rapid pAKTS473 response to serum stimulation
in cells lackingMYO1C compared to the control cells (Fig 7B). This fast response was time lim-
ited and the level of pAKTS473 rapidly diminished, reaching a significantly lower level com-
pared to the control cells after 20 min (Fig 7B). In this experiment we chose to examine only
the pAKTS473 response, as the basal phosphorylation at residue S473 is the initial step for acti-
vation of AKT and only after this basal activation can the AKT protein become fully activated
through the second phosphorylation at its residue T308.
MYO1C is shown to tightly bind to Rictor, which is a downstream protein in the PI3K/AKT
pathway that can make a complex with the mammalian target of rapamycin complex 2
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(mTORC2). This complex is responsible for the basal activation of AKT through phosphoryla-
tion of its Serine 473 residue [56, 57]. Interestingly, in their study, Hagen et al. concluded that
the Rictor-mTORC2 complex is independent of the Rictor-MYO1C complex, and also that
MYO1C was not required for mTORC2-dependent AKT activation in 3T3-L1 adipocytes [56,
57]. They found that with increasing doses of insulin, Rictor knockdown cells showed a reduc-
tion in the level of pAKTS473 compared to control cells, whereas MYO1C-depleted cells did not
show a similar effect [56, 57]. It is of note that Hagan et al. looked at the insulin stimulation
effects on transfected cells at only one time point (15 min). In our study, using a different cell
type (MCF10A), we could clearly show that depletion of MYO1C resulted in a rapid increased
level of pAKTS473 at 5 min post stimulation that was significantly reduced after 20 min.
Accordingly, it is possible that the previous studies [56, 57] with their experimental design
missed the strong and rapid activation of AKT in response to MYO1C depletion.
Here we hypothesize that in the presence of MYO1C, as it tightly binds to Rictor, the Rictor-
mTORC2 complex may not fully function, hence phosphorylation of AKT at its Serine 473 resi-
due is become impaired (Fig 6). With the same logic, in the absence of MYO1C, the Rictor protein
is set free to make a complex withmTORC2 and thus to phosphorylate AKT (Fig 7A and 7B).
However, our experiment design suggests that the dynamic betweenRictor-mTORC2 and Rictor-
MYO1C complexes may not be as simple as proposed above. In cells expressing normal levels of
MYO1C (Fig 7B, white bars), over time a linear increase of the pAKTS473 levels in response to the
serum stimulation was observed.However, in cells lackingMYO1C (Fig 7B, dark bars), there was
a fast pAKTS473 response that rapidly went to the other direction and after 20 min reached a sig-
nificantly lower level in cells with diminishedMYO1C compared to control cells. It appears in the
MYO1C depleted cells the hyper-activated Rictor-mTORC2 complex is becoming quickly
exhausted and not able to exert its function as efficiently over time.Whether the presence of
MYO1C is required for the stability of Rictor and/or stability of the Rictor-mTORC2 complex is
an interesting research question for further investigation. Taken together, our results suggest that
normal levels of MYO1C are required for normal function of the Rictor-mTORC2 complex and
whenMYO1C is lacking or its expression is disturbed, the AKT signaling is deregulated in favor
of hyper-activation of PI3K/AKT signaling, and towards tumorous features.
Conclusion
Results from the present work provide evidence for inhibitory function ofMYO1C on cell pro-
liferation, presumably through repression of PI3K/AKT signaling, hence supporting the initial
hypothesis of tumor suppressor activity for this gene. We additionally showed that reduced
MYO1C expression resulted in diminished cell migration and impaired cell adhesion; pheno-
types that may contribute to loss of “contact inhibition”. These outcomes are additional sup-
porting evidences for the proposed tumor suppressor characteristic ofMYO1C. Finally, we
found that the MYO1C protein level was reduced in endometrial carcinomas and that this
reduced expression was significantly different between tumors and hyperplasia samples.
Over-activation of the PI3K/AKT signaling pathway contributes to the development of
most cancer types, hence identification of newly described tumor suppressor gene associated
with this pathway would offer novel routes of cancer treatment strategies. Further studies are
required to fully understand details of the contribution ofMYO1C to carcinogenesis and to
address the above-mentioned hypotheses and questions.
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